Amir Jazaeri, MD, Professor, Vice Chair, Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery at MD Anderson Cancer Center. In this video, he speaks about Immuno-Oncology for Gynecologic Malignancies.
Â
Overview:
Currently, available cytotoxic and targeted therapy provide minimal benefit to patients with advanced and/or recurrent gynecologic malignancies. Immunotherapy’s success in other difficult-to-treat cancers, including metastatic melanoma and advanced lung cancer, has sparked a surge of interest in clinical trials in patients with gynecologic tumors. The FDA-approved use of immune checkpoint inhibitors in gynecologic oncology is currently confined to tumors with high microsatellite instability, cancers with high tumor mutational load, and PD-L1-positive cervical carcinoma. Clinical trials evaluating immunotherapy techniques in patients with gynecologic tumors have grown at an exponential rate, both alone and in conjunction with chemotherapy and/or targeted medicines. This chapter will go over some of the most well-known and current immunotherapy clinical trials in endometrial, cervical, and epithelial ovarian cancer patients.